Urinary Cell Levels of mRNA for OX40, OX40L, PD-1, PD-L1, or PD-L2 and Acute Rejection of Human Renal Allografts

被引:47
|
作者
Afaneh, Cheguevara [1 ]
Muthukumar, Thangamani [2 ,3 ]
Lubetzky, Michelle [2 ]
Ding, Ruchuang [2 ]
Snopkowski, Catherine [2 ]
Sharma, Vijay K. [2 ,4 ]
Seshan, Surya [5 ]
Dadhania, Darshana [2 ,3 ,4 ]
Schwartz, Joseph E. [6 ]
Suthanthiran, Manikkam [2 ,3 ]
机构
[1] New York Presbyterian Hosp, Weill Cornell Med Ctr, Dept Surg, New York, NY USA
[2] New York Presbyterian Hosp, Weill Cornell Med Ctr, Div Nephrol & Hypertens, Dept Med, New York, NY USA
[3] New York Presbyterian Hosp, Weill Cornell Med Ctr, Dept Transplantat Med, New York, NY USA
[4] Rogosin Inst, New York, NY USA
[5] New York Presbyterian Hosp, Weill Cornell Med Ctr, Dept Pathol, New York, NY USA
[6] SUNY Stony Brook, Dept Psychiat, Stony Brook, NY 11794 USA
基金
新加坡国家研究基金会;
关键词
Acute rejection; OX40; Costimulation; Urinary biomarkers; RESPONSES IN-VIVO; COSTIMULATORY PATHWAYS; ALLOIMMUNE RESPONSES; TRANSPLANT RECIPIENTS; T-CELLS; TOLERANCE; ACCEPTANCE; SURVIVAL; BLOCKING; MEMORY;
D O I
10.1097/TP.0b013e3181ffbadd
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. The positive costimulatory proteins OX40 and OX40L and negative regulatory proteins programmed death (PD)-1, PD ligand 1, and PD ligand 2 have emerged as significant regulators of acute rejection in experimental transplantation models. Methods. We obtained 21 urine specimens from 21 renal allograft recipients with graft dysfunction and biopsy-confirmed acute rejection and 25 specimens from 25 recipients with stable graft function and normal biopsy results (stable). Urinary cell levels of mRNAs were measured using real-time quantitative polymerase chain reaction assays, and the levels were correlated with allograft status and outcomes. Results. Levels of OX40 mRNA (P < 0.0001, Mann-Whitney test), OX40L mRNA (P = 0.0004), and PD-1 mRNA (P = 0.004), but not the mRNA levels of PD ligand 1 (P = 0.08) or PD ligand 2 (P = 0.20), were significantly higher in the urinary cells from the acute rejection group than the stable group. Receiver operating characteristic curve analysis demonstrated that acute rejection is predicted with a sensitivity of 95% and a specificity of 92% (area under the curve = 0.98, 95% confidence interval 0.96-1.0, P < 0.0001) using a combination of levels of mRNA for OX40, OX40L, PD-1, and levels of mRNA for the previously identified biomarker Foxp3. Within the acute rejection group, levels of mRNA for OX40 (P = 0.0002), OX40L (P = 0.0004), and Foxp3 (P = 0.04) predicted acute rejection reversal, whereas only OX40 mRNA levels (P = 0.04) predicted graft loss after acute rejection. Conclusion. A linear combination of urinary cell levels of mRNA for OX40, OX40L, PD-1, and Foxp3 was a strong predictor of acute rejection in human renal allograft biopsies. This prediction model should be validated using an independent cohort of renal allograft recipients.
引用
收藏
页码:1381 / 1387
页数:7
相关论文
共 50 条
  • [41] Prognostic value of PD-1, PD-L1 and PD-L2 deserves attention in head and neck cancer
    Jiang, Siqing
    Li, Xin
    Huang, Lihua
    Xu, Zhensheng
    Lin, Jinguan
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [42] EXPRESSION OF PD-1, PD-L1 AND PD-L2 IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES AND ITS CLINIC RELATIONSHIP
    Geng, S.
    Weng, J.
    Deng, C.
    Li, M.
    Lu, Z.
    Wu, P.
    Huang, X.
    Lai, P.
    Du, X.
    LEUKEMIA RESEARCH, 2017, 55 : S112 - S112
  • [43] High-affinity PD-1 molecules deliver improved interaction with PD-L1 and PD-L2
    Li, Yanyan
    Liang, Zhaoduan
    Tian, Ye
    Cai, Wenxuan
    Weng, Zhiming
    Chen, Lin
    Zhang, Huanling
    Bao, Yifeng
    Zheng, Hongjun
    Zeng, Sihai
    Bei, Chunhua
    Li, Yi
    CANCER SCIENCE, 2018, 109 (08): : 2435 - 2445
  • [44] Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade
    Bai, Jie
    Gao, Zhitao
    Li, Xiang
    Dong, Liang
    Han, Weidong
    Nie, Jing
    ONCOTARGET, 2017, 8 (66) : 110693 - 110707
  • [45] The role of antagonists of the PD-1: PD-L1/PD-L2 axis in head and neck cancer treatment
    Pai, Sara I.
    Zandberg, Dan P.
    Strome, Scott E.
    ORAL ONCOLOGY, 2016, 61 : 152 - 158
  • [46] AKT/mTOR Signal Cascade and Expression of PD-1, PD-L1, and PD-L2 in Gastric Cancer
    L. V. Spirina
    A. V. Avgustinovich
    S. G. Afanas’ev
    I. V. Kondakova
    M. Yu. Volkov
    A. Yu. Dobrodeev
    A. I. Boronkina
    Bulletin of Experimental Biology and Medicine, 2020, 170 : 75 - 78
  • [47] Evaluation of PD-L1, PD-L2, PD-1 and cytotoxic immune response in oral lichen planus
    Costa, Nadia Lago
    Goncalves, Julie Ane Maria
    de Lima, Sara Lia Goncalves
    de Arruda, Jose Alcides Almeida
    Miranda, Ana Carolina Campos
    Mesquita, Ricardo Alves
    da Silveira, Ericka Janine Dantas
    Batista, Aline Carvalho
    ORAL DISEASES, 2020, 26 (06) : 1246 - 1254
  • [48] The PD-1 pathway in systemic lupus erythematosus: The Ligands of PD-1, PD-L1 and PD-L2, are also susceptibility factors.
    Abelson, AK
    Johansson, C
    Kozyrev, S
    ARTHRITIS AND RHEUMATISM, 2004, 50 (09): : S203 - S203
  • [49] Immune Checkpoint (PD-1, PD-L1, PD-L2, and CTLA-4) Expression in Plasma Cell Myeloma
    Lee, Min Young
    Park, Chan-jeoung
    Cho, Young-Uk
    You, Eunkyoung
    Jang, Seongsoo
    Lee, Jung-Hee
    Hong, Jung Yong
    Yoon, Dok Hyun
    Suh, Cheolwon
    BLOOD, 2017, 130
  • [50] PD-L1 and PD-L2 expression in colorectal cancer
    Zeynep, Ozgul
    Funda, Canaz
    Evrim, Yilmaz
    Deniz, Arik
    Bulent, Yildiz
    Fatih, Yasar. N.
    INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY, 2023, 66 (01) : 31 - 37